title: Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".
abstract: In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.
authors.affiliation: Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Charité Universitätsmedizin Berlin, Campus Charité Mitte, Berlin. alexander.nast@charite.de
authors.forename: Alexander
authors.initials: A
authors.lastname: Nast
authors.forename: Matthias
authors.initials: M
authors.lastname: Augustin
authors.forename: Wolf-Henning
authors.initials: WH
authors.lastname: Boehncke
authors.forename: Joachim
authors.initials: J
authors.lastname: Klaus
authors.forename: Ulrich
authors.initials: U
authors.lastname: Mrowietz
authors.forename: Hans-Michael
authors.initials: HM
authors.lastname: Ockenfels
authors.forename: Sandra
authors.initials: S
authors.lastname: Philipp
authors.forename: Kristian
authors.initials: K
authors.lastname: Reich
authors.forename: Thomas
authors.initials: T
authors.lastname: Rosenbach
authors.forename: Martin
authors.initials: M
authors.lastname: Schlaeger
authors.forename: Michael
authors.initials: M
authors.lastname: Sebastian
authors.forename: Wolfram
authors.initials: W
authors.lastname: Sterry
authors.forename: Volker
authors.initials: V
authors.lastname: Streit
authors.forename: Peter
authors.initials: P
authors.lastname: Weisenseel
authors.forename: Berthold
authors.initials: B
authors.lastname: Rzany
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003880:Dermatology / Q000592:standards*; D005062:European Union; D019317:Evidence-Based Medicine; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab